Bupivacaine
From WikiAnesthesia
Revision as of 19:26, 6 September 2021 by Olivia Sutton (talk | contribs) (Started article, filled out summary table)
Bupivacaine
| Trade names |
Marcaine |
|---|---|
| Clinical data | |
| Drug class |
Local Anesthetic |
| Uses |
Regional anesthesia, neuraxial anesthesia |
| Contraindications |
Allergy (rare), bier block (due to risk of tourniquet failure and systemic drug absorption causing cardiac arrest) |
| Routes of administration |
Intrathecal, epidural, peripheral nerve block, local infiltration |
| Dosage |
Maximum dose: 2-2.5mg/kg, not to exceed 175mg per dose or 400mg/24h Spinal anesthesia: commonly 7.5-12mg of 0.75% bupivacaine for C-section under spinal |
| Pharmacodynamics | |
| Mechanism of action |
Sodium channel blockade |
| Adverse effects |
Cardiotoxicity, LAST |
| Pharmacokinetics | |
| Onset of action |
Within 15 mins |
| Duration of action |
2-8h |
| Metabolism |
Liver |
| Elimination half-life |
approx 3h |
| Protein binding |
95% |
| Physical and chemical data | |
| Article quality | |
| Editor rating | |
| User likes | 0 |
Provide a brief summary of this drug here.